vs
Side-by-side financial comparison of MicroAlgo Inc. (MLGO) and Neuphoria Therapeutics Inc. (NEUP). Click either name above to swap in a different company.
MicroAlgo Inc. is the larger business by last-quarter revenue ($26.3M vs $15.0M, roughly 1.8× Neuphoria Therapeutics Inc.).
MicroAlgo Inc. is a technology enterprise specializing in custom algorithm optimization solutions. It mainly serves clients across smart city management, industrial internet, and e-commerce sectors, helping enterprises improve operational efficiency, reduce operating costs, and optimize data processing performance for real business scenarios.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
MLGO vs NEUP — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.3M | $15.0M |
| Net Profit | — | $11.3M |
| Gross Margin | — | — |
| Operating Margin | — | 79.8% |
| Net Margin | — | 75.1% |
| Revenue YoY | -35.5% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $6.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $26.3M | — | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | $34.6M | — | ||
| Q2 24 | $40.8M | — | ||
| Q2 23 | $20.2M | — | ||
| Q1 23 | $17.8M | — | ||
| Q2 22 | $28.2M | — | ||
| Q1 22 | $23.4M | — |
| Q2 25 | — | — | ||
| Q1 25 | — | $11.3M | ||
| Q4 24 | $4.2M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | $-4.8M | — | ||
| Q1 23 | $-1.3M | — | ||
| Q2 22 | $-23.6K | — | ||
| Q1 22 | $888.4K | — |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 26.4% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | 33.0% | — | ||
| Q1 23 | 27.8% | — | ||
| Q2 22 | -0.1% | — | ||
| Q1 22 | 23.1% | — |
| Q2 25 | — | — | ||
| Q1 25 | — | 79.8% | ||
| Q4 24 | 7.0% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | -7.7% | — | ||
| Q1 23 | -7.9% | — | ||
| Q2 22 | -0.1% | — | ||
| Q1 22 | 5.0% | — |
| Q2 25 | — | — | ||
| Q1 25 | — | 75.1% | ||
| Q4 24 | 12.1% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | -23.7% | — | ||
| Q1 23 | -7.1% | — | ||
| Q2 22 | -0.1% | — | ||
| Q1 22 | 3.8% | — |
| Q2 25 | — | — | ||
| Q1 25 | — | $6.55 | ||
| Q4 24 | $0.56 | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $319.4M | $17.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $317.6M | $26.0M |
| Total Assets | $330.8M | $30.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $319.4M | — | ||
| Q1 25 | — | $17.0M | ||
| Q4 24 | $164.9M | — | ||
| Q2 24 | $66.7M | — | ||
| Q2 23 | $19.2M | — | ||
| Q1 23 | $21.0M | — | ||
| Q2 22 | $10.9K | — | ||
| Q1 22 | $28.7K | — |
| Q2 25 | $317.6M | — | ||
| Q1 25 | — | $26.0M | ||
| Q4 24 | $144.9M | — | ||
| Q2 24 | $76.0M | — | ||
| Q2 23 | $60.4M | — | ||
| Q1 23 | $66.7M | — | ||
| Q2 22 | $-3.0M | — | ||
| Q1 22 | $-2.5M | — |
| Q2 25 | $330.8M | — | ||
| Q1 25 | — | $30.7M | ||
| Q4 24 | $176.3M | — | ||
| Q2 24 | $107.6M | — | ||
| Q2 23 | $71.8M | — | ||
| Q1 23 | $75.6M | — | ||
| Q2 22 | $47.3M | — | ||
| Q1 22 | $46.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $11.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q1 25 | — | $11.5M | ||
| Q4 24 | $4.8M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | $-3.8M | — | ||
| Q1 23 | $-2.8M | — | ||
| Q2 22 | $-747.8K | — | ||
| Q1 22 | $456.6K | — |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.8M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | $-2.8M | — | ||
| Q2 22 | — | — | ||
| Q1 22 | $270.9K | — |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.8% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | -15.8% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | 1.2% | — |
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q2 23 | — | — | ||
| Q1 23 | 0.3% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | 0.8% | — |
| Q2 25 | — | — | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | 1.15× | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | 0.51× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
